December 2015

Contents

Editorial

• Nov/Dec 2015: Volume 16 Number 11/12

Conference reports

• 15th European AIDS Conference (EACS), 21-24 October 2015, Barcelona

• Remarkable results with dolutegravir monotherapy

• First-line ART with dolutegravir plus 3TC: 24-week early results

• New European HIV guidelines (October 2015): universal ART, first-line integrase and PrEP

• Impact of early ART on lung function: results on ART and COPD from START substudy

• No difference in neuropsychological test results between early and delayed ART in START substudy

• Immediate ART in START linked to greater bone loss over three years

• Price of MDR TB drugs could be greatly reduced with competitive generic manufacture

• Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23

• Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

• French cohort of HIV transgender women highlights issues relating to HIV management

• 7th International Workshop on HIV Paediatrics, 17-18 July, Vancouver, Canada

• Substituting lopinavir/ritonavir with efavirenz in children on stable ART

• The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression

• Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB

Antiretrovirals

• Tenofovir alafenamide (TAF) approved – but only as part of a fixed dose combination

Treatment access

• CHAI’s ARV market report predicts that new drugs and formulations will drive the next major drop in treatment costs

• New trade agreements threaten treatment access in Asia

Guidelines

• European HIV guidelines updated (October 2015)

• New UK guidelines on use of vaccines in HIV positive adults (2015)

• IAS-USA update resistance guidelines and mutation tables (2015)

Hepatitis coinfection

• NICE decision on ledipasvir/sofosbuvir for chronic HCV

• Sofosbuvir/velpatasvir submitted to US FDA for HCV genotype 1-6

• US indication for ledipasvir/sofosbuvir expanded

HIV prevention and transmission

• HIV rates still increasing in gay men: 2015 report

• PrEP to be available free in France from January 2016

• PrEP efficacy for transgender women: new analysis from iPrEX study

• PrEP in a clinical setting: no infections reported in San Francisco cohort

• New free self-sampling HIV home testing service launched in England

Research studies

• Why START would make an excellent long-term cohort

• Why dolutegravir might get us closer to ending AIDS: next step, further research

PDFs

• November/December 2015: Volume 16 Number 11/12